Diabetes 'technological wave' has too much upside to ignore

[mannmade]

www.cnbc.com/2018/06/08/diabetes-technological-wave-has-too-much-upside-to-ignore-jp-morgan.html


Diabetes 'technological wave' has too much upside to ignore: JP Morgan
The ongoing changes to glucose monitoring are so important, Marcus added, that medical device companies such as Dexcom are set for "significant" upside.
"The diabetes space is currently experiencing its biggest technological wave of innovation from glucose measurement to insulin dosing," analyst Robbie Marcus wrote Friday.
Dexcom's stock is up more than 62 percent so far this year. Shares extended their 2018 gains Friday, climbing nearly 4 percent.
Thomas Franck | @tomwfranck
Published 3:59 PM ET Fri, 8 June 2018 Updated 6:35 PM ET Fri, 8 June 2018
CNBC.com
After the sensor warmed up, it was off by 25 mg.
CNBC | Erin Black
After the sensor warmed up, it was off by 25 mg.
New technologies for diabetes treatment are becoming essential for those who suffer from the disease, according to J.P. Morgan, and that could make companies such as Dexcom compelling investment opportunities.

"The diabetes space is currently experiencing its biggest technological wave of innovation from glucose measurement (continuous glucose monitoring) to insulin dosing (insulin pumps)," analyst Robbie Marcus said in a note to clients Friday. "CGM is becoming an essential tool for patients and is now at the level of sensitivity that it is eliminating the need for fingersticks with blood glucose monitoring."

Technological advances for glucose checking are so important, Marcus added, that medical device companies such as Dexcom are set for "significant" upside over the next few years. Marcus upgraded shares of Dexcom to overweight and raised his price target on the company to $115 from $80, implying 28 percent upside over the next year.

Dexcom, which produces devices that attach to a patient's skin to monitor blood-glucose levels continuously, has the potential to crush consensus revenue estimates, the analyst added. He predicts that the San Diego-based company could reach $876 million this year, which would beat expectations of $860 million.

CNBC's Erin Black inserts the Dexcom G6 sensor This diabetes monitor can read your blood sugar without any blood
8:56 AM ET Sat, 12 May 2018 | 03:16
"Treatment is shifting towards integrated pumps where the CGM dictates insulin dosing, and in our view the CGM is the much more valuable component of that equation than the pump," Marcus explained. "We think the Street is being too conservative on the near-term sustainability of Dexcom's hardware business (transmitters and receivers) and assuming a significant headwind to both new patient adds and base business patient attrition."

Dexcom's stock is up more than 62 percent so far this year. Shares extended their 2018 gains Friday, climbing nearly 4 percent.

"One of the hidden assets of Dexcom is this investment we've made in technology," chief executive Kevin Sayer told "Mad Money" host Jim Cramer in November. "Our system offers features that competitors don't. We connect to phones. We share data with people who watch patients. We offer performance and accuracy that others don't."

[mannmade]

The relevance of the above article imho to mnkd long is that TIR will most likely become the standard measurement over Hba1c with the sucess of CGM's. And we know no other product on the market helps manage TIR better than Afrezza.

[peppy]

www.youtube.com/watch?v=C-DnznA0m9k

[sayhey24]

We have been talking about CGMs and how important they will become for well over 2 years on this board. When I first met Mike when he was the CMO, the majority of the discussion was around the coming importance of CGMs and that CGMs will save afrezza. Prior, doctors could simply hide from the numbers.

The next step is going beyond monitoring and addressing the meal time spike. Kevin Sayer has done a great job to date. He took Al's invention and made a company out of it. CGMs will become a commodity market and the Cloud Service companies will pick and choose. At the end of the day they need to go beyond monitoring and address the root cause - not enough insulin at meal time.

If I were Kevin, I would be thinking about getting into the afrezza business. He has the share price and Mike has the solution. Kevin has been in the background since MNKD was started and I think its time for him to step out of the shadows. What did Kevin say three years ago at ADA2015 about afrezza? - he's never seen anything like it.

[peppy]

Jun 10, 2018 10:26:50 GMT -5 sayhey24 said:

We have been talking about CGMs and how important they will become for well over 2 years on this board. When I first met Mike when he was the CMO, the majority of the discussion was around the coming importance of CGMs and that CGMs will save afrezza. Prior, doctors could simply hide from the numbers.

The next step is going beyond monitoring and addressing the meal time spike. Kevin Sayer has done a great job to date. He took Al's invention and made a company out of it. CGMs will become a commodity market and the Cloud Service companies will pick and choose. At the end of the day they need to go beyond monitoring and address the root cause - not enough insulin at meal time.

If I were Kevin, I would be thinking about getting into the afrezza business. He has the share price and Mike has the solution. Kevin has been in the background since MNKD was started and I think its time for him to step out of the shadows. What did Kevin say three years ago at ADA2015 about afrezza? - he's never seen anything like it.

None of us have ever seen anything like the way afrezza works on blood glucose levels until we saw the continuous glucose monitors. That is why the endocrinologist not prescribing afrezza makes no sense. Until we learn how health insurance/pharmacy really works. Their hands are tied?